When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TRVI - Trevi Therapeutics under pressure after increasing size of Haduvio study
Trevi Therapeutics Inc.
Thinly traded nano cap Trevi Therapeutics (TRVI-17.7%) is under modest pressure on turnover of only 27K shares in reaction to its announcement that, based on a recommendation from the independent Data Monitoring Committee (DMC), it will increase target enrollment to 360 from 240 in its Phase 2b/3 clinical trial, PRISM, evaluating oral Haduvio (nalbuphine extended-release) in patients with severe pruritis (itchy skin) associated with prurigo nodularis, a skin disorder characterized by hard itchy lumps. It has also increased the number of trial sites to 60.
More news on: Trevi Therapeutics, Inc., Healthcare stocks news, Stocks on the move,